Development of dual inhibitors targeting pyruvate dehydrogenase kinases and human lactate dehydrogenase A: High-throughput virtual screening, synthesis and biological validation

Sichuan Xiang,Ding Huang,Qiaolin He,Jie Li,Kin Yip Tam,Shao-Lin Zhang,Yun He

DOI: https://doi.org/10.1016/j.ejmech.2020.112579

IF: 7.088

2020-10-01

European Journal of Medicinal Chemistry

Abstract:<p>Most cancer cells feature an altered glucose metabolism from oxidative phosphorylation to cytoplasmic glycolysis. Pyruvate dehydrogenase kinases (PDKs) and lactate dehydrogenase A (LDHA) play crucial roles in promotion of glycolysis, thus the inhibition of both enzymes is considered a promising strategy for developing of anticancer therapeutics. Herein, we describe the first discovery of series novel dual inhibitors targeting PDKs and LDHA. We identified 6 hits from a library database containing 485465 compounds through a high-throughput virtual screening assay. Hit-to-lead optimization enabled us to discover two compounds, namely <strong>20e</strong> and <strong>20k</strong>, which inhibited PDKs with IC₅₀ values of 0.8, and 1.6 μM, respectively, and inhibited LDHA with IC₅₀ values of 0.15 and 0.7 μM, respectively. Meanwhile, the two compounds reduced A549 cell proliferation with EC₅₀ values of 13.2, and 15.7 μM. Furthermore, <strong>20e</strong> and <strong>20k</strong> decreased the lactate formation, and increased oxygen consumption, suggesting the two compounds modulated the glucose metabolic pathways in cancer cells.</p>

chemistry, medicinal